title: Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer.
abstract: 9-cis-Retinoic acid (9-cis-RA) and all-trans-RA (ATRA) are naturally occurring hormones. The nuclear receptors that mediate the effects of retinoids are the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). ATRA binds RAR with high affinity but does not bind to RXR, whereas 9-cis-RA, an isomer of ATRA, is a ligand that binds and transactivates both RARs and RXRs. The goals of this study were to determine the safety, tolerability, pharmacokinetics, and metabolic profile of 9-cis-RA in advanced cancer patients. Forty-one patients received oral 9-cis-RA (ALRT1057; Panretin capsules) at doses ranging from 5-140 mg/m2/day. Twenty-six patients were treated once daily with up to 140 mg/m2; a subsequent cohort of 15 patients were treated twice daily (b.i.d.) at 100-140 mg/m2/day (50, 60, and 70 mg/m2 b.i.d.) to evaluate a b.i.d. dosing regimen. Headache was the most frequent adverse event and was dose limiting in 3 of 41 patients. Skin toxicity was the next most common toxicity and was seen in 11 of 41 patients; it was typically mild and limited to skin dryness and erythema. Other toxicities included conjunctivitis, flushing, diarrhea, transaminitis, hypercalcemia, and asymptomatic hypertryglyceridemia. Toxicities were typically dose related, occurred primarily above 83 mg/m2/day, and were not ameliorated by b.i.d. dosing. No tumor responses were observed. The mean day 1 area under the plasma concentration-time curve and peak plasma concentration values were dose-proportional over all dose levels, whereas day 15 area under the plasma concentration-time curve and peak plasma concentration values were nonlinear above 83 mg/m2/day, suggesting that 9-cis-RA induced its own metabolism at doses equal to and above 140 mg/m2/day. 9-cis-RA is a retinoid receptor pan agonist with a more favorable pharmacokinetic and toxicity profile than that observed with previously studied retinoids and merits further investigation.
authors.affiliation: Department of Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, D.C. 20007, USA.
authors.forename: N A
authors.initials: NA
authors.lastname: Rizvi
authors.forename: J L
authors.initials: JL
authors.lastname: Marshall
authors.forename: E
authors.initials: E
authors.lastname: Ness
authors.forename: J
authors.initials: J
authors.lastname: Yoe
authors.forename: G M
authors.initials: GM
authors.lastname: Gill
authors.forename: J A
authors.initials: JA
authors.lastname: Truglia
authors.forename: G R
authors.initials: GR
authors.lastname: Loewen
authors.forename: D
authors.initials: D
authors.lastname: Jaunakais
authors.forename: E H
authors.initials: EH
authors.lastname: Ulm
authors.forename: M J
authors.initials: MJ
authors.lastname: Hawkins
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000077556:Alitretinoin; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity*; D002214:Capsules; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D014212:Tretinoin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity*
chemical_list: D000970:Antineoplastic Agents; D002214:Capsules; D000077556:Alitretinoin; D014212:Tretinoin